Rheumatology Advance Access originally published online on February 8, 2007
Rheumatology 2007 46(4):724; doi:10.1093/rheumatology/kem009
© The Author 2007. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
SF-36 Scales in the Relaxin study
D. Khanna,
G. S. Park1 and
J. Seibold2
University of Cincinnati and VAMC, Cincinnati, OH, 1UCLA Medical Center, Los Angeles, CA 2University of Michigan, Ann Arbor, MI, USA
Correspondence to: Dinesh Khanna, MD, MSc, Assistant Professor of Medicine, Division of Immunology, Section of Rheumatology, 231 Albert Sabin Way, PO Box 670563, Cincinnati, OH 45267-0563, USA. E-mail: dinesh.khanna{at}uc.edu
SIR, Georges et al. [1], in their original publication, report the raw scores for the SF-36 scales and norm-based summary scores in their cohort of subjects with systemic sclerosis (SSc). In Table 5, they refer our article [2], stating that we did not provide data on the SF-36 scales. As the purpose of our original study was to examine the responsiveness to change of the SF-36 summary scores and Health Assessment Questionnaire-Disability Index, we presented the summary scores. Our analysis was conducted on data collected from the Relaxin study that assessed the efficacy of Relaxin in early diffuse SSc [3]. In this letter, we provide both baseline raw and norm-based scores for the SF-36 scales for 196 patients who completed the study (Table 1), so comparisons can be made with present and future SF-36 publications in SSc. Since we used version 1 of the SF-36, we recalculated the scores using the 1998 norms [4]. Therefore, the mean values of the summary scores differ slightly from what was reported in our original article [2]. Our revised analysis is based on the assumption that Georges et al. used SF-36 version 2 (which uses 1998 norms) since their study was conducted from 2001 to 2004.
 |
References
|
|---|
- Georges C, Chassany O, Toledano C, et al. (2006) Impact of pain in health related quality of life of patients with systemic sclerosis. Rheumatology 45:1298302.[Abstract/Free Full Text]
- Khanna D, Furst DE, Clements PJ, et al. (2005) Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. J Rheumatol 32:83240.[Abstract/Free Full Text]
- Seibold J, Clements P, Korn JH, et al. (2001) U.S. phase III trial of relaxin in diffuse scleroderma. J Rheumatol (Abstract) 63:T-64.
- Ware JE, Kosinski M, Dewey JE. (2000) How to Score Version Two of the SF-36 Health Survey.(QualityMetric, Incorporated, Lincoln, RI).
Accepted 3 January 2007

CiteULike
Connotea
Del.icio.us What's this?